Crinetics Pharmaceuticals (CRNX) Q2 2025 earnings summary

Executive summary

• Paltusotine (PALSONIFY) is under FDA review for acromegaly with a PDUFA date of September 25, 2025, and EMA decision expected in H1 2026; commercial and medical launch preparations are nearly complete.

• Deep pipeline includes late-stage and early-stage programs for atumelnant (CAH, Cushing’s), CRN09682, and other hormone antagonists, with multiple clinical trials advancing.

• Strong engagement with patients, advocacy groups, and healthcare professionals shapes commercial strategy and drives awareness and education.

• No products approved for sale yet; revenue is derived from license and supply agreements.

• Commercial and clinical teams are prepared for U.S. and EU launches, with international expansion planned for 2026.

Financial highlights

• Q2 2025 revenue was $1.0 million, up 158% year-over-year, mainly from licensing and supply agreements.

• R&D expenses rose to $80.3 million and SG&A expenses to $49.8 million in Q2 2025, both up significantly year-over-year.

• Net loss for Q2 2025 was $115.6 million, compared to $74.1 million in Q2 2024.

• Cash, cash equivalents, and investments totaled $1.2 billion at June 30, 2025, supporting operations into 2029.

• Net cash used in operations for the first half of 2025 was $174.3 million, up 73% year-over-year.

Outlook and guidance

• Cash runway is projected to fund operations into 2029, with 2025 net cash use guidance narrowed to $340–$370 million.

• PALSONIFY U.S. launch expected post-approval, with formulary placement anticipated to take 6–9 months; European launch targeted for 2026.

• Expenses and operating losses are expected to increase as late-stage trials and commercialization accelerate.

• Multiple clinical trial initiations planned for H2 2025 and H1 2026.